Spruce Biosciences (SPRB) Payables (2019 - 2026)

Spruce Biosciences (SPRB) posted quarterly Payables of $298000.0 for Q1 2026, down 68.4% quarter-over-quarter from $943000.0 in Q4 2025.

Spruce Biosciences (SPRB) Payables (2019 - 2026) Analysis & Trends

Spruce Biosciences (SPRB) has reported Payables for 8 consecutive years, with $298000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Payables changed N/A year-over-year to $298000.0; the TTM figure through Mar 2026 stood at $298000.0 (changed N/A YoY), while the FY2025 annual figure was $943000.0, down 27.18% from the prior year.
Payables eased to $298000.0 in Q1 2026 per SPRB's latest filing, from $943000.0 in the prior quarter.
Across five years, Payables topped out at $3.4 million in Q1 2023 and bottomed at $298000.0 in Q1 2026.
Historically, Payables has averaged $1.6 million across 5 years, with a median of $1.4 million in 2022.
Annual changes were most pronounced in 2023 — Payables jumped 210.91% — and 2024, when it sank 61.13%.
Spruce Biosciences' Payables stood at $1.4 million in 2022, then surged by 133.66% to $3.3 million in 2023, then tumbled by 61.13% to $1.3 million in 2024, then decreased by 27.18% to $943000.0 in 2025, then sank by 68.4% to $298000.0 in 2026.
Business Quant data shows SPRB's Payables at $298000.0 in Q1 2026, $943000.0 in Q4 2025, and $1.4 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Payables (Qtr)
1	Vertex Pharmaceuticals	138.81 Bn	130.96 Bn	2.84 Bn	429.50 Mn
2	Regeneron Pharmaceuticals	86.07 Bn	78.08 Bn	3.93 Bn	1.16 Bn
3	Argenx Se	65.47 Bn	60.29 Bn	1.37 Bn	1.52 Bn
4	Moderna	55.64 Bn	50.50 Bn	52.00 Mn	167.00 Mn
5	BeOne Medicines	41.99 Bn	36.89 Bn	1.53 Bn	470.30 Mn
6	Alnylam Pharmaceuticals	31.68 Bn	28.37 Bn	992.69 Mn	108.02 Mn
7	BioNTech SE	27.69 Bn	9.29 Bn	668.28 Mn	622.65 Mn
8	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	428.93 Mn
9	Royalty Pharma	27.36 Bn	26.52 Bn	-	35.57 Mn
10	Spruce Biosciences	122.59 Mn	122.59 Mn	-	1.21 Mn

Download Data